NLRP3 as a potentially novel biomarker for the management of osteoarthritis

Megan McAllister; Melody El Chemaly; Amanda J Eakin; David S Gibson; Victoria E McGilligan

doi:10.1016/j.joca.2018.02.901

NLRP3 as a potentially novel biomarker for the management of osteoarthritis

Megan McAllister, Melody El Chemaly, Amanda J Eakin, David S Gibson, Victoria E McGilligan

Research output: Contribution to journal › Article › peer-review

147 Citations (Scopus)

53 Downloads (Pure)

Abstract

Osteoarthritis was previously thought of as ‘wear and tear’ as humans age, however there is increasing evidence to support an inflammatory theory. The NLRP3 inflammasome has been implicated in the pathogenesis of a number of arthritic disorders, producing proinflammatory cytokines and degradative enzymes such as IL-1β, TNF-α and MMP-3 which drive cartilage degeneration and synovial inflammation. This review aims to summarise the evidence of NLRP3 involvement in osteoarthritis. Currently, treatment options focus on management of the disease and to date there is no cure. The development of novel biomarkers for osteoarthritis could improve diagnosis, treatment and management. Importantly, this review provides detail on the involvement of the NLRP3 inflammasome in osteoarthritis pathology and how its members could act as potential biomarkers to assist clinical decisions.

Original language	English
Pages (from-to)	612–619
Number of pages	8
Journal	Osteoarthritis and Cartilage
Volume	26
Issue number	5
DOIs	https://doi.org/10.1016/j.joca.2018.02.901
Publication status	Published (in print/issue) - 31 May 2018

Keywords

Osteoarthritis
NLRP3
inflammasome
biomarker
inflammation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.joca.2018.02.901

MMcA Manuscript Clean Copy 060218Author Accepted Manuscript, 41.8 KB

https://doi.org/10.1016/j.joca.2018.02.901

Cite this

@article{7afe766ec07343b3bd5cc99c9c89ef02,

title = "NLRP3 as a potentially novel biomarker for the management of osteoarthritis",

abstract = "Osteoarthritis was previously thought of as {\textquoteleft}wear and tear{\textquoteright} as humans age, however there is increasing evidence to support an inflammatory theory. The NLRP3 inflammasome has been implicated in the pathogenesis of a number of arthritic disorders, producing proinflammatory cytokines and degradative enzymes such as IL-1β, TNF-α and MMP-3 which drive cartilage degeneration and synovial inflammation. This review aims to summarise the evidence of NLRP3 involvement in osteoarthritis. Currently, treatment options focus on management of the disease and to date there is no cure. The development of novel biomarkers for osteoarthritis could improve diagnosis, treatment and management. Importantly, this review provides detail on the involvement of the NLRP3 inflammasome in osteoarthritis pathology and how its members could act as potential biomarkers to assist clinical decisions.",

keywords = "Osteoarthritis, NLRP3, inflammasome, biomarker, inflammation",

author = "Megan McAllister and {El Chemaly}, Melody and Eakin, {Amanda J} and Gibson, {David S} and McGilligan, {Victoria E}",

year = "2018",

month = may,

day = "31",

doi = "10.1016/j.joca.2018.02.901",

language = "English",

volume = "26",

pages = "612–619",

journal = "Osteoarthritis and Cartilage",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - NLRP3 as a potentially novel biomarker for the management of osteoarthritis

AU - McAllister, Megan

AU - El Chemaly, Melody

AU - Eakin, Amanda J

AU - Gibson, David S

AU - McGilligan, Victoria E

PY - 2018/5/31

Y1 - 2018/5/31

N2 - Osteoarthritis was previously thought of as ‘wear and tear’ as humans age, however there is increasing evidence to support an inflammatory theory. The NLRP3 inflammasome has been implicated in the pathogenesis of a number of arthritic disorders, producing proinflammatory cytokines and degradative enzymes such as IL-1β, TNF-α and MMP-3 which drive cartilage degeneration and synovial inflammation. This review aims to summarise the evidence of NLRP3 involvement in osteoarthritis. Currently, treatment options focus on management of the disease and to date there is no cure. The development of novel biomarkers for osteoarthritis could improve diagnosis, treatment and management. Importantly, this review provides detail on the involvement of the NLRP3 inflammasome in osteoarthritis pathology and how its members could act as potential biomarkers to assist clinical decisions.

AB - Osteoarthritis was previously thought of as ‘wear and tear’ as humans age, however there is increasing evidence to support an inflammatory theory. The NLRP3 inflammasome has been implicated in the pathogenesis of a number of arthritic disorders, producing proinflammatory cytokines and degradative enzymes such as IL-1β, TNF-α and MMP-3 which drive cartilage degeneration and synovial inflammation. This review aims to summarise the evidence of NLRP3 involvement in osteoarthritis. Currently, treatment options focus on management of the disease and to date there is no cure. The development of novel biomarkers for osteoarthritis could improve diagnosis, treatment and management. Importantly, this review provides detail on the involvement of the NLRP3 inflammasome in osteoarthritis pathology and how its members could act as potential biomarkers to assist clinical decisions.

KW - Osteoarthritis

KW - NLRP3

KW - inflammasome

KW - biomarker

KW - inflammation

U2 - 10.1016/j.joca.2018.02.901

DO - 10.1016/j.joca.2018.02.901

M3 - Article

C2 - 29499288

VL - 26

SP - 612

EP - 619

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

IS - 5

ER -

NLRP3 as a potentially novel biomarker for the management of osteoarthritis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this